Kyverna Therapeutics (NASDAQ:KYTX) Rating Lowered to Sell at Wall Street Zen

Key Points

• Wall Street Zen downgraded Kyverna from "hold" to "sell," while Weiss Ratings also maintains a sell rating even as Morgan Stanley and Wells Fargo have higher $33 price targets and MarketBeat's consensus remains a "Moderate Buy" with a $28.67 target.
• Kyverna shares opened at $7.94 with a market cap of about $347.8M, a negative P/E (-2.13), and a 52-week range of $1.78–$13.67, trading near its 50- and 200-day moving averages.
• Several institutions have recently increased or initiated positions—Price T. Rowe, Adage, AIGH, Vanguard and Balyasny among them—leaving roughly 18.08% of the stock owned by institutional investors.

Kyverna Therapeutics (NASDAQ:KYTX - Get Free Report) was downgraded by investment analysts at Wall Street Zen from a "hold" rating to a "sell" rating in a research report issued on Saturday.

A number of other analysts have also recently commented on the company. Morgan Stanley set a $33.00 price objective on Kyverna Therapeutics in a research report on Monday, December 15th. Wells Fargo & Company lifted their price target on shares of Kyverna Therapeutics from $31.00 to $33.00 and gave the company an "overweight" rating in a research note on Tuesday, December 16th. Finally, Weiss Ratings reissued a "sell (d-)" rating on shares of Kyverna Therapeutics in a report on Monday, December 29th. Four investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $28.67.

Kyverna Therapeutics Stock Performance

KYTX opened at $7.94 on Friday. The company has a fifty day moving average of $8.36 and a two-hundred day moving average of $7.44. The stock has a market capitalization of $347.77 million, a price-to-earnings ratio of -2.13 and a beta of 3.32. Kyverna Therapeutics has a fifty-two week low of $1.78 and a fifty-two week high of $13.67.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in KYTX. Price T Rowe Associates Inc. MD increased its stake in shares of Kyverna Therapeutics by 16.6% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 1,762,617 shares of the company's stock worth $16,569,000 after acquiring an additional 250,418 shares during the last quarter. Adage Capital Partners GP L.L.C. acquired a new position in shares of Kyverna Therapeutics during the 4th quarter valued at about $15,667,000. AIGH Capital Management LLC purchased a new stake in shares of Kyverna Therapeutics in the fourth quarter valued at about $14,100,000. Vanguard Group Inc. grew its holdings in shares of Kyverna Therapeutics by 0.8% in the third quarter. Vanguard Group Inc. now owns 1,322,625 shares of the company's stock valued at $7,936,000 after purchasing an additional 9,858 shares during the period. Finally, Balyasny Asset Management L.P. acquired a new stake in Kyverna Therapeutics during the fourth quarter worth about $9,220,000. 18.08% of the stock is currently owned by institutional investors and hedge funds.

About Kyverna Therapeutics

Kyverna Therapeutics is a clinical‐stage biotechnology company dedicated to developing engineered regulatory T‐cell (Treg) therapies for the treatment of autoimmune and inflammatory diseases. Leveraging a proprietary platform for the isolation, expansion and modification of Treg cells, the company aims to restore immune homeostasis in patients by delivering antigen‐specific cell therapies that selectively target diseased tissues while minimizing systemic immunosuppression.

The company's lead programs include an allogeneic Treg candidate in clinical development for ulcerative colitis, with additional preclinical assets focused on rheumatoid arthritis and other chronic inflammatory conditions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.